Jerry White
Cardiovascular Disease · Ashland, KYNPI 1245655968
Payments from drug & device makers
Across 410 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Pfizer$738
- AstraZeneca$615
- Cvrx, Inc.$291
- Abbott$255
- plus $2K from 23 others
What the payments were for
- Food & beverage$6,71599%
- Education$831%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 137 | $1,940 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 91 | $1,348 |
| Pfizer | 58 | $738 |
| AstraZeneca | 14 | $615 |
| Cvrx, Inc. | 14 | $291 |
| Abbott | 9 | $255 |
| E.r. Squibb & Sons, L.L.C. | 12 | $184 |
| Boehringer Ingelheim | 11 | $174 |
| Amgen | 6 | $156 |
| Philips North America LLC | 5 | $140 |
| Johnson & Johnson | 10 | $135 |
| Boston Scientific | 6 | $112 |
| Merck | 8 | $112 |
| United Therapeutics Corporation | 5 | $88 |
| Novo Nordisk | 4 | $80 |
| Heartflow, Inc. | 1 | $76 |
| Inspire Medical Systems, Inc. | 2 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Bayer | 2 | $35 |
| Medtronic(2 entities) | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Mylan Specialty L.p. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Viatris Specialty LLC | 1 | $21 |
| Shockwave Medical, Inc | 1 | $17 |
| ZOLL Circulation Inc | 1 | $15 |
| Siemens Medical Solutions USA, Inc. | 1 | $14 |
| Convatec Inc. | 1 | $13 |
How this compares
$6,798 in reported general payments places this provider in the 75th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 96 | $90,311 |
| EntrestoSacubitril/Valsartan | 51 | $56,861 |
| XareltoRivaroxaban | 15 | $15,696 |
| Repatha SureclickEvolocumab | 20 | $15,532 |
| JardianceEmpagliflozin | 20 | $15,062 |
| FarxigaDapagliflozin Propanediol | 13 | $11,603 |
| Ranolazine ErRanolazine | 99 | $8,008 |
| Metoprolol Succinate | 386 | $4,416 |
| Rosuvastatin Calcium | 344 | $3,213 |
| Atorvastatin Calcium | 199 | $1,675 |
| Losartan Potassium | 164 | $991 |
| Flecainide Acetate | 25 | $887 |
| Amlodipine Besylate | 178 | $868 |
| Furosemide | 192 | $727 |
| Lisinopril | 117 | $710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $738 | $90,31196 claims |
| NovartisEntresto | $1,940 | $56,86151 claims |
| Johnson & JohnsonXarelto | $135 | $15,69615 claims |
| Boehringer IngelheimJardiance | $174 | $15,06220 claims |
| AstraZenecaFarxiga | $615 | $11,60313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Ashland
- Kishor VoraOwensboro$4.5M
- Dinesh KalraLouisville$739K
- Amir PirachaLouisville$590K
- Rohan SamsonLouisville$527K
- Shahab GhafghaziLouisville$404K
- William SkinnerLexington$346K
- Vipul PanchalLouisville$301K
- John KotterLexington$241K
- John HarrisLouisville$226K
- Suresh SharmaLexington$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.